Clinical Trial Update: Multiple Dosing of Mesenchymal Stromal Cells in Patients With ARDS (COVID-19) [Phase 2]

View source ↗

Summary

Phase 2 trial results for multiple dosing of mesenchymal stromal cells in patients with acute respiratory distress syndrome related to COVID-19; the study has c…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Respiratory Distress Syndrome

Drugs mentioned

• Mesenchymal stromal cells

Snippet

Sponsor: Masonic Cancer Center, University of Minnesota | Conditions: Acute Respiratory Distress Syndrome, ARDS (Moderate or Severe) | Phase 2 | Status: COMPLETED | Results posted: 2024-10-01